Weight LossResearch

Mazdutide Therapy: Complete Guide

Mazdutide is a dual GLP-1 and glucagon receptor agonist licensed by Innovent Biologics from Eli Lilly. It was approved in China in 2025 for weight management, making it one of the first glucagon co-agonists approved anywhere. It is not FDA-approved and is not legally available in the United States. US readers encountering it online should understand that no domestic supply route is lawful.

Written by
Megan Williams
Editor-in-Chief
Fact-checked by
Brian Williams
Co-founder & Research Editor
Last updated
August 5, 2026

Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.

What is Mazdutide?

Mazdutide is a dual GLP-1 and glucagon receptor agonist licensed by Innovent Biologics from Eli Lilly. It was approved in China in 2025 for weight management, making it one of the first glucagon co-agonists approved anywhere. It is not FDA-approved and is not legally available in the United States. US readers encountering it online should understand that no domestic supply route is lawful.

How Mazdutide Works

Mazdutide works through specific biological pathways to produce its therapeutic effects. Consult with a qualified provider for detailed information about how this peptide therapy works for your specific condition.

Benefits & Uses

Approved in China for chronic weight management, with a separate approval there for glycaemic control in type 2 diabetes. Dual glucagon activity is intended to increase energy expenditure alongside appetite suppression.

Clinical Evidence & Research

Clinical research on Mazdutide continues to evolve. Mazdutide has been studied in preclinical and clinical settings. Speak with your provider about the current evidence base.

Side Effects & Safety

Gastrointestinal effects typical of the incretin class — nausea, diarrhoea, vomiting — most common during dose escalation. Because it is not FDA-reviewed, US prescribers have no approved labelling to work from.

Dosing & Administration

Dosing protocols for Mazdutide should be determined by a qualified healthcare provider based on your individual health profile, treatment goals, and response to therapy. Self-dosing without medical supervision is not recommended.

Find Mazdutide Providers Near You

Search our directory for qualified providers offering Mazdutide therapy. Filter by location, telehealth, and more.

Browse Providers

Mazdutide FAQ

Approved in China for chronic weight management, with a separate approval there for glycaemic control in type 2 diabetes. Dual glucagon activity is intended to increase energy expenditure alongside appetite suppression.

Costs vary by provider and location. Contact providers directly for current pricing.

Mazdutide has an FDA status of "Research". It is currently used in research and clinical settings. Consult with a qualified provider about its regulatory status and appropriate use.

Gastrointestinal effects typical of the incretin class — nausea, diarrhoea, vomiting — most common during dose escalation. Because it is not FDA-reviewed, US prescribers have no approved labelling to work from.

PeptideProbe lists 0 providers offering Mazdutide therapy. Use our directory to search by location, filter by telehealth availability, and compare providers.

What Mazdutide is used for

Each of these reviews the evidence for that goal, including where it is weaker than the marketing suggests.

Stay Updated

Get notified when new peptide therapy providers join in your area.

Related Peptides

Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.